Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapy

25 Apr 2019

Abstract excerpt

Abstract UTX (also known as KDM6A), a histone 3 lysine 27 demethylase, is among the most frequently mutated epigenetic regulators in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Recent studies have suggested that UTX mutations promote MDS and AML by blocking the differentiation of hematopoietic stem and progenitor cells (HSPCs). Here, we performed an epigenetic drug library screening for small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31044091
DOI: 10.1038/s41392-019-0040-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic drug library screening identified an LSD1 inhibitor to target UTX-deficient cells for differentiation therapyPMID 31044091Read ↗

Advances Toward Lsd1 Inhibitors for Cancer TherapySemantic proximity Read ↗

Utx loss causes myeloid transformation.Semantic proximity Read ↗

Lysine-specific demethylase 1A restricts ex vivo propagation of human HSCs and is a target of UM171Semantic proximity Read ↗

Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes.Semantic proximity Read ↗

LSD1 as a promising target for various diseases treatment through cell stemness regulationSemantic proximity Read ↗

Targeting lysine demethylase 6B ameliorates ASXL1 truncation–mediated myeloid malignancies in preclinical modelsSemantic proximity Read ↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1, a novel oncogene in AMLSemantic proximity Read ↗

Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AMLSemantic proximity Read ↗

Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1 oncogenic functions in AMLSemantic proximity Read ↗

Inhibitors of LSD1 as a potential therapy for acute myeloid leukemiaSemantic proximity Read ↗

UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.Semantic proximity Read ↗

Identification and validation of prognosis‐related DLX5 methylation as an epigenetic driver in myeloid neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.